Physician profile
Lesley A Inker
NPI 1659482743
$30,206.94
in general payments reported to CMS, 2019-2025
9 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2022: $113 · 2023: $2,038 · 2024: $18K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $1,243 · Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,682.50 |
| Travel and Lodging | $1,242.90 |
| Food and Beverage | $999.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $13,644.00 | 2023-2025 | |
| Astrazeneca Uk Limited | $11,325.00 | 2023-2025 | |
| Sarepta Therapeutics, INC. | $4,800.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $169.66 | 2019 | |
| Travere Therapeutics, INC. | $155.54 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.74 | 2022 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Inker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.